# Domain Analysis: Oligopeptide Educational Website Project

**Document ID:** DOM-ANALYSIS-001
**Version:** 1.0.0
**Date:** 2026-06-07
**Status:** Approved
**Author:** Automated Domain Analysis

---

## Table of Contents

1. [Executive Summary](#1-executive-summary)
2. [Domain Scope](#2-domain-scope)
3. [Oligopeptide Domain Analysis](#3-oligopeptide-domain-analysis)
4. [Audience Analysis](#4-audience-analysis)
5. [Content Strategy Distinction Matrix](#5-content-strategy-distinction-matrix)
6. [Technical Domain Constraints](#6-technical-domain-constraints)
7. [Risk Assessment](#7-risk-assessment)
8. [Multi-lingual Requirements](#8-multi-lingual-requirements)

---

## 1. Executive Summary

This document provides a rigorous domain analysis for two complementary oligopeptide educational websites: **encyclopeptide.com** (formal encyclopedic reference) and **wikipept.com** (collaborative wiki-style educational platform). The project targets the intersection of biochemistry education, pharmacological reference, and computational biology resource provision.

### 1.1 Project Scope Overview

The oligopeptide domain spans molecules composed of 2–20 amino acid residues linked by peptide bonds, representing a critical intermediate class between individual amino acids and larger polypeptide/protein structures. Oligopeptides serve essential roles in cell signaling, antimicrobial defense, neurotransmission, hormonal regulation, and represent a rapidly expanding class of therapeutic agents with projected global market value exceeding $12.8 billion by 2030.

### 1.2 Dual-Site Strategy Rationale

The bifurcated approach addresses two fundamentally distinct user intent patterns:

- **Encyclopedic intent**: Users seeking authoritative, citable, peer-reviewed-grade data on specific oligopeptide structures, synthesis routes, and pharmacokinetic parameters. This population demands precision, traceability, and formal scientific notation.
- **Educational intent**: Users seeking to learn about oligopeptides from foundational concepts through expert-level material, leveraging community knowledge, interactive assessment tools, and progressive disclosure of complexity.

### 1.3 Key Deliverables

| Deliverable          | encyclopeptide.com                                | wikipept.com                                              |
| -------------------- | ------------------------------------------------- | --------------------------------------------------------- |
| Primary content type | Monographs, data tables, molecular visualizations | Study guides, tutorials, community annotations            |
| Citation model       | DOI-linked, peer-reviewed references              | Community-sourced, editable footnotes                     |
| Interactivity level  | 3D molecular viewer, structure search             | Quizzes, flashcards, spaced repetition, progress tracking |
| Editing model        | Editorial board review                            | Wiki-style collaborative editing                          |
| Visual identity      | Clinical, journal-like                            | Warm, card-based, modern wiki                             |

---

## 2. Domain Scope

### 2.1 In-Scope

#### 2.1.1 Oligopeptide Classification Systems

The following classification axes are within scope for both sites, though presented with different levels of depth and formality:

**By Chain Length:**

- Dipeptides (2 residues): e.g., carnosine (β-alanyl-L-histidine), anserine (β-alanyl-L-1-methylhistidine)
- Tripeptides (3 residues): e.g., glutathione (γ-L-glutamyl-L-cysteinylglycine), thyrotropin-releasing hormone (TRH)
- Tetrapeptides (4 residues): e.g., kyotophin, epigram (epitalon)
- Pentapeptides (5 residues): e.g., oxytocin (9 residues, but historically classified alongside oligopeptides), angiotensin II (8 residues), kyotorphin
- Hexapeptides (6 residues): e.g., ACTH fragments, enkephalin analogs
- Heptapeptides (7 residues): e.g., thymopentin (TP-5)
- Octapeptides (8 residues): e.g., angiotensin II, arginine vasopressin
- Nonapeptides (9 residues): e.g., oxytocin, vasopressin
- Decapeptides (10 residues): e.g., gonadorelin, nisin fragments
- Undeca- to Icosapeptides (11–20 residues): e.g., cyclosporine (11 residues, cyclic), some antimicrobial peptides

**By Functional Class:**

- Neurotransmitter modulators (enkephalins, endorphins, dynorphins)
- Hormonal regulators (TRH, GnRH, oxytocin, vasopressin analogs)
- Antimicrobial peptides (nisin, subtilisin, gramicidin S fragments)
- Immunomodulatory peptides (thymopentin,胸腺五肽, tuftsin)
- Antioxidant peptides (glutathione, carnosine)
- ACE-inhibitory peptides (lactokinins, casokinins)
- Bioactive food peptides (soy peptides, whey peptides, collagen-derived)
- Neuropeptides (substance P fragments, cholecystokinin fragments)

**By Source Organism:**

- Mammalian (endogenous peptides, milk-derived, blood-derived)
- Microbial (bacterial, fungal, archaeal)
- Marine organisms (sponges, corals, marine bacteria, mollusks)
- Plant-derived (wheat gluten peptides, soy peptides)
- Synthetic/combinatorial library peptides

**By Structural Features:**

- Linear oligopeptides
- Cyclic oligopeptides (head-to-tail, head-to-side-chain, side-chain-to-side-chain)
- D-amino acid-containing peptides
- Modified peptides (phosphorylated, glycosylated, methylated, acetylated)
- Peptidomimetics (partial structural mimics)
- Branched peptides

**By Therapeutic Application:**

- Oncology (cytotoxic peptides, tumor-homing peptides)
- Infectious disease (antimicrobial, antiviral)
- Endocrinology (hormone analogs, receptor agonists/antagonists)
- Neurology (analgesic, neuroprotective)
- Dermatology (wound healing, anti-aging)
- Metabolic disorders (GLP-1 analogs, insulin sensitizers)
- Cardiovascular (ACE inhibitors, natriuretic peptide fragments)

#### 2.1.2 Biochemical Knowledge Domain

- Amino acid chemistry (20 standard + non-standard amino acids)
- Peptide bond formation mechanisms (condensation, ribosomal vs. non-ribosomal synthesis)
- Peptide stability and degradation pathways (proteolytic enzymes, half-life determination)
- Structure-activity relationships (SAR) for bioactive oligopeptides
- Receptor binding pharmacology (Ki, Kd, IC50, EC50 values)
- Pharmacokinetic parameters (absorption, distribution, metabolism, excretion for peptide drugs)
- Peptide synthesis methodologies (solid-phase peptide synthesis, solution-phase, recombinant production)
- Analytical characterization (HPLC, mass spectrometry, NMR, circular dichroism, X-ray crystallography)
- Computational peptide design (molecular dynamics, docking, QSAR, machine learning approaches)

#### 2.1.3 Educational Content Domain

- Foundational biochemistry (amino acid structure, peptide bond, primary/secondary/tertiary structure)
- Intermediate concepts (receptor pharmacology, signal transduction, metabolic pathways)
- Advanced topics (non-ribosomal peptide synthesis, peptide engineering, computational design)
- Cross-disciplinary connections (bioinformatics, systems biology, chemical biology)
- Historical context (discovery timelines, Nobel Prize contributions, paradigm shifts)
- Clinical translation (drug development pipeline, regulatory considerations, market landscape)

#### 2.1.4 Technical Features

**encyclopeptide.com:**

- 3D molecular viewer integration (Mol\*, NGL Viewer, or 3Dmol.js)
- IUPAC nomenclature rendering
- SMILES/InChI structure representation
- Reaction pathway diagrams (synthesis routes)
- Structured data tables with sortable/filterable parameters
- DOI-linked citation management
- Structure-based search (substructure, similarity)
- API access for programmatic data retrieval

**wikipept.com:**

- Quiz and flashcard engine (SM-2/FSRS spaced repetition algorithm)
- Progress tracking (learning streaks, mastery levels, knowledge maps)
- Community annotation system (inline comments, footnotes, ratings)
- Comparison table builder (side-by-side peptide property comparison)
- Visual mnemonic generator
- Contribution leaderboard and reputation system
- Version history and edit diff visualization
- Import/export of study decks (Anki, Quizlet compatibility)

#### 2.1.5 Reference Data Sources

- UniProt (protein/peptide sequence database)
- PDB (Protein Data Bank - 3D structural data)
- ChEMBL/DrugBank (pharmacological activity data)
- PubChem (chemical compound data)
- PeptideAtlas (peptide identification data)
- APD (Antimicrobial Peptide Database)
- BioPEPT (bioactive peptide database)
- IUPHAR/BPS Guide to Pharmacology (receptor/ligand data)
- ClinicalTrials.gov (active clinical studies)
- literature (PubMed, Google Scholar indexed)

### 2.2 Out-of-Scope

The following domains are explicitly excluded to maintain focus and prevent scope creep:

#### 2.2.1 Excluded Molecular Classes

- Individual amino acids (monomers) — except as building blocks for oligopeptide context
- Proteins (>20 residues) — except as precursors or context for oligopeptide release
- Nucleic acids, lipids, carbohydrates — except where directly interacting with oligopeptide targets
- Small molecule drugs — except as peptidomimetics or comparative reference
- Polysaccharides, glycolipids

#### 2.2.2 Excluded Content Types

- Bench protocols or laboratory SOPs (not a methods database)
- Clinical patient-facing treatment recommendations (not a medical advice platform)
- Patent filing or IP strategy guidance (not a legal resource)
- Commercial product advertising or endorsement
- Equipment or reagent vendor catalogs
- Animal model protocols (except brief contextual references)

#### 2.2.3 Excluded Technical Features

- Real-time experimental data feeds
- LIMS (Laboratory Information Management System) integration
- Electronic lab notebook functionality
- Gene synthesis ordering integration
- Clinical trial management
- Electronic health record (EHR) integration
- Real-time collaboration on documents (beyond wiki-style sequential editing)

#### 2.2.4 Excluded Audiences (as primary targets)

- Patients seeking medical advice or self-treatment guidance
- Legal professionals (patent attorneys, regulatory consultants)
- Investors or business analysts (market intelligence)
- Equipment sales representatives
- General news media (not a press resource)

---

## 3. Oligopeptide Domain Analysis

### 3.1 Chemistry Foundation

#### 3.1.1 Peptide Bond Chemistry

The peptide bond (amide bond, –CO–NH–) connecting amino acid residues is the fundamental structural unit of all oligopeptides. Key characteristics requiring accurate representation:

**Electronic Structure:**

- Resonance stabilization: The peptide bond exhibits ~40% double-bond character due to resonance between the carbonyl oxygen and amide nitrogen
- Restricted rotation: The C–N bond has a rotational barrier of approximately 60–90 kJ/mol, imposing planarity on the peptide unit
- Trans/cis isomerism: The trans configuration (ω ≈ 180°) is energetically preferred over cis (ω ≈ 0°) by approximately 8–20 kJ/mol due to steric clash between Cα substituents
- Proline exception: cis-trans isomerization is kinetically accessible for X-Pro peptide bonds, with biological significance in protein folding

**Conformational Nomenclature:**

- Ramachandran plot parameters (φ, ψ angles)
- Secondary structure designations (α-helix, β-sheet, β-turn, polyproline helix, random coil)
- Turn classifications (type I, II, II', III, IV, VI turns)
- Special structural motifs (β-hairpin, helix-turn-helix, zinc finger motifs in larger structures)

**Notation Requirements:**

- IUPAC-IUB nomenclature for amino acid abbreviations (3-letter and 1-letter codes)
- Peptide sequence notation: N-terminus → C-terminus convention
- Modification notation: standard abbreviations for post-translational modifications
- Stereochemistry: L/D designations, absolute configuration

#### 3.1.2 Amino Acid Building Blocks

Complete characterization of the 20 standard proteinogenic amino acids:

| Code | Name          | Side chain class             | pKa (side chain) | Hydropathy Index | Molecular Weight |
| ---- | ------------- | ---------------------------- | ---------------- | ---------------- | ---------------- |
| G    | Glycine       | Nonpolar, aliphatic          | —                | -0.4             | 75.03            |
| A    | Alanine       | Nonpolar, aliphatic          | —                | 1.8              | 89.09            |
| V    | Valine        | Nonpolar, aliphatic          | —                | 4.2              | 117.15           |
| L    | Leucine       | Nonpolar, aliphatic          | —                | 3.8              | 131.17           |
| I    | Isoleucine    | Nonpolar, aliphatic          | —                | 4.5              | 131.17           |
| P    | Proline       | Nonpolar, aliphatic (cyclic) | —                | -1.6             | 115.13           |
| F    | Phenylalanine | Nonpolar, aromatic           | —                | 2.8              | 165.19           |
| W    | Tryptophan    | Nonpolar, aromatic           | —                | -0.9             | 204.23           |
| M    | Methionine    | Nonpolar, sulfur-containing  | —                | 1.9              | 149.21           |
| S    | Serine        | Polar, uncharged             | 13.6             | -0.8             | 105.09           |
| T    | Threonine     | Polar, uncharged             | 13.6             | -0.7             | 119.12           |
| C    | Cysteine      | Polar, sulfur-containing     | 8.18             | 2.5              | 121.16           |
| Y    | Tyrosine      | Polar, aromatic              | 10.07            | -1.3             | 181.19           |
| N    | Asparagine    | Polar, amide                 | —                | -3.5             | 132.12           |
| Q    | Glutamine     | Polar, amide                 | —                | -3.5             | 146.15           |
| D    | Aspartate     | Acidic                       | 3.65             | -3.5             | 133.10           |
| E    | Glutamate     | Acidic                       | 4.25             | -3.5             | 147.13           |
| K    | Lysine        | Basic                        | 10.53            | -3.9             | 146.19           |
| R    | Arginine      | Basic                        | 12.48            | -4.5             | 174.20           |
| H    | Histidine     | Basic, aromatic              | 6.00             | -3.2             | 155.16           |

Non-standard amino acids of particular importance to oligopeptide biology:

- Hydroxyproline (Hyp) — collagen-derived peptides
- Phosphoserine/phosphothreonine/phosphotyrosine — signaling peptides
- Selenocysteine (Sec) — selenopeptides
- Pyrrolysine (Pyl) — archaeal peptides
- D-amino acid residues — non-ribosomal peptide products
- β-amino acids — peptidomimetics (e.g., β-alanine in carnosine)
- N-methylated amino acids — cyclosporine, some marine peptides

#### 3.1.3 Peptide Synthesis Pathways

**Biosynthetic (Ribosomal) Pathway:**

- Translation machinery: ribosomes, tRNAs, aminoacyl-tRNA synthetases
- Post-translational processing: signal peptide cleavage, prohormone conversion
- Proteolytic maturation: endopeptidase and exopeptidase processing
- Enzymatic modifications: glycosylation, phosphorylation, hydroxylation, cyclization

**Non-Ribosomal Peptide Synthesis (NRPS):**

- Multi-enzyme complexes (NRPS synthetases)
- Template-directed assembly (A-T-C domain architecture)
- Incorporation of non-proteinogenic amino acids
- Modification domains (cyclization, methylation, halogenation, oxidation)
- Examples: vancomycin, cyclosporine, gramicidin, bacitracin

**Chemical Synthesis:**

- Solid-Phase Peptide Synthesis (SPPS): Fmoc and Boc strategies
  - Resin types: Wang, Rink amide, 2-chlorotrityl, Merrifield
  - Coupling reagents: HATU, HBTU, TBTU, EDC/HOBt, PyBOP
  - Deprotection strategies and side-chain protection schemes
  - Cleavage cocktails: TFA-based, HF-based
- Solution-Phase Synthesis: segment condensation, native chemical ligation
- Recombinant Production: expression in E. coli, yeast, mammalian cells, plant systems
- Hybrid Approaches: semi-synthesis, chemoenzymatic synthesis

**Analytical Characterization Methods:**

- Mass spectrometry: MALDI-TOF, ESI-MS, tandem MS/MS
- HPLC: reverse-phase, ion-exchange, size-exclusion, chiral
- NMR spectroscopy: 1D (¹H, ¹³C), 2D (COSY, TOCSY, NOESY, HSQC, HMBC)
- Circular dichroism (CD) spectroscopy
- X-ray crystallography (for larger oligopeptides/complexes)
- Cryo-electron microscopy (emerging for oligopeptide-receptor complexes)
- Capillary electrophoresis
- Edman degradation (for sequencing verification)

#### 3.1.4 Stability and Degradation

**Chemical Degradation Pathways:**

- Hydrolysis: acid-catalyzed and base-catalyzed amide bond cleavage
- Oxidation: methionine sulfoxide formation, cysteine disulfide scrambling, tryptophan oxidation
- Deamidation: asparagine → isoaspartate/aspartate conversion, glutamine → glutamate
- Racemization: base-catalyzed L→D amino acid inversion
- β-elimination: phosphoserine dephosphorylation and elimination
- Maillard reaction: N-terminal amino group with reducing sugars

**Enzymatic Degradation:**

- Endopeptidases: trypsin (Lys/Arg), chymotrypsin (Phe/Trp/Tyr), elastase (Ala/Val/Ser)
- Exopeptidases: aminopeptidases, carboxypeptidases
- Dipeptidyl peptidases (DPP-IV, DPP-8, DPP-9)
- Neprilysin (enkephalinase)
- Angiotensin-converting enzyme (ACE)

**Stabilization Strategies:**

- D-amino acid substitution at vulnerable positions
- Cyclization (head-to-tail, side-chain-to-side-chain)
- N-methylation of backbone amides
- PEGylation and lipidation
- Microencapsulation and nanoparticle formulation
- Sequence optimization (removing labile residues)

### 3.2 Biology Domain

#### 3.2.1 Biosynthesis and Processing

**Ribosomal Pathway Detail:**

- Prepropeptide → Propeptide → Mature peptide processing hierarchy
- Signal peptidase I/II cleavage in ER lumen
- Prohormone convertases (PC1/3, PC2, furin, PC5/6, PACE4, PC7)
- Carboxypeptidase E/H processing
- Amidation by peptidylglycine α-amidating monooxygenase (PAM)
- Disulfide bond formation by protein disulfide isomerase (PDI)

**Non-Ribosomal Biosynthesis:**

- NRPS module organization: adenylation (A), thiolation (T/PCP), condensation (C) domains
- Starter, elongation, and termination modules
- Collinearity rule and its exceptions
- Hybrid NRPS-PKS (polyketide synthase) systems
- Post-assembly tailoring reactions

**Secretion and Distribution:**

- Constitutive vs. regulated secretory pathways
- Dense-core vesicle storage and stimulus-dependent release
- Peptide transport mechanisms (PEPT1/SLC15A1, PEPT2/SLC15A2)
- Blood-brain barrier penetration considerations
- Renal clearance mechanisms (glomerular filtration, tubular reabsorption)

#### 3.2.2 Receptor Interactions

**Receptor Classification:**

- G-protein coupled receptors (GPCRs): largest class of oligopeptide receptors
  - Class A (Rhodopsin-like): most peptide receptors
  - Class B (Secretin-like): calcitonin, GLP-1, PTH receptors
  - Class C (Glutamate-like): GABA-B (responds to GABA, but conceptually relevant)
- Ionotropic receptors: ligand-gated ion channels (some neuropeptide modulatory sites)
- Enzyme-linked receptors: receptor tyrosine kinases (some respond to oligopeptide ligands)
- Intracellular receptors: cytoplasmic/nuclear targets (some steroid hormone interactions with peptides)

**Binding Kinetics Parameters:**

- Dissociation constant (Kd): typically nanomolar range for bioactive peptides
- Association rate constant (kon): diffusion-limited or conformationally controlled
- Dissociation rate constant (koff): determines functional duration of action
- Residence time (τ = 1/koff): increasingly recognized as key pharmacological parameter
- Binding cooperativity: Hill coefficient for multi-site binding

**Signal Transduction Cascades:**

- Gαs → adenylyl cyclase → cAMP → PKA pathway
- Gαi → inhibition of adenylyl cyclase
- Gαq → PLC → IP₃ + DAG → Ca²⁺ release + PKC activation
- Gα12/13 → RhoGEF → cytoskeletal remodeling
- β-arrestin recruitment → biased agonism, receptor internalization
- Receptor dimerization and cross-talk

#### 3.2.3 Physiological Roles

**Cell Signaling:**

- Autocrine signaling (local self-regulation)
- Paracrine signaling (nearby cell communication)
- Endocrine signaling (systemic hormonal regulation)
- Synaptic signaling (neurotransmitter/neuromodulator function)

**Immune Function:**

- Antimicrobial peptide activity mechanisms (membrane disruption, intracellular targets)
- Immunomodulatory peptide signaling (cytokine-like activities)
- Tumor-associated antigen peptide presentation (MHC class I/II)

**Metabolic Regulation:**

- Insulin/glucagon axis modulation
- Incretin effect (GLP-1, GIP)
- Appetite regulation (orexigenic vs. anorexigenic peptides)
- Calcium homeostasis (PTH, calcitonin fragments)

**Neural Function:**

- Neuropeptide Y (NPY) — feeding behavior, stress response
- Substance P — pain transmission, inflammation
- Cholecystokinin (CCK) — satiety, anxiety
- Orexin/hypocretin — wakefulness regulation
- Endorphins/enkephalins — analgesia, reward

### 3.3 Pharmacology Domain

#### 3.3.1 Therapeutic Oligopeptide Landscape

**Market Categories:**

| Category       | Examples                                    | Global Market (2025 est.) | CAGR  |
| -------------- | ------------------------------------------- | ------------------------- | ----- |
| Metabolic      | Semaglutide, Liraglutide, Exenatide         | $4.2B                     | 12.4% |
| Oncology       | Lutathera (¹⁷⁷Lu-DOTATATE), Plitidepsin     | $1.8B                     | 15.2% |
| Antimicrobial  | Nisin (food), Dalbavancin derivatives       | $0.9B                     | 8.7%  |
| Cardiovascular | Sacubitril (prodrug → neprilysin inhibitor) | $1.4B                     | 9.1%  |
| Neurological   | Enkephalin analogs, Ziconotide              | $0.6B                     | 11.3% |
| Bone/Joint     | Teriparatide (PTH 1-34), Ziconotide         | $0.8B                     | 7.4%  |
| Rare diseases  | Various orphan peptides                     | $0.5B                     | 18.6% |

**Drug Development Pipeline Considerations:**

- Peptide drug attrition rates vs. small molecules vs. biologics
- ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) challenges
- Oral bioavailability limitations (typically <2% without modification)
- Formulation strategies: injectable, nasal, oral (with permeation enhancers), transdermal, implantable
- Manufacturing scalability: SPPS vs. recombinant vs. fermentation
- Regulatory pathways: NDA, BLA, 505(b)(2), ANDA for peptide generics
- Patent landscape: composition of matter, formulation, method of use, process patents

#### 3.3.2 Pharmacokinetic Parameters

Essential parameters for therapeutic oligopeptide characterization:

| Parameter              | Symbol | Units       | Typical Range (peptides) |
| ---------------------- | ------ | ----------- | ------------------------ |
| Bioavailability        | F      | %           | 1–50 (route-dependent)   |
| Volume of distribution | Vd     | L/kg        | 0.05–0.5                 |
| Clearance              | CL     | mL/min/kg   | 1–10                     |
| Half-life              | t₁/₂   | min–hr      | 2 min–24 hr              |
| Maximum concentration  | Cmax   | ng/mL–μg/mL | variable                 |
| Time to maximum        | Tmax   | min–hr      | 0.25–4 hr                |
| Area under curve       | AUC    | ng·hr/mL    | variable                 |
| Protein binding        | PB     | %           | 10–99                    |
| Renal clearance        | CLr    | mL/min/kg   | 0.5–5                    |

**Route-Specific Considerations:**

- Intravenous: 100% bioavailability, first-pass metabolism eliminated
- Subcutaneous: variable absorption, lymphatic contribution
- Intramuscular: moderate absorption rate
- Oral: significant barriers (acid degradation, enzymatic digestion, poor permeation)
- Nasal: nasal mucosa absorption, olfactory pathway access
- Pulmonary: large surface area, thin epithelium, but mucus barrier
- Transdermal: microneedle patches, iontophoresis, chemical enhancers

#### 3.3.3 Safety and Toxicology

**Common Adverse Effects of Therapeutic Peptides:**

- Injection site reactions (redness, swelling, pain)
- Gastrointestinal effects (nausea, vomiting, diarrhea — especially GLP-1 agonists)
- Immunogenicity (anti-drug antibody formation)
- Hypoglycemia (insulin and insulin secretagogues)
- Hypocalcemia/hypercalcemia (calcium-regulating peptides)
- Hepatotoxicity (rare, but documented for some peptides)

**Toxicology Assessment Methods:**

- Acute toxicity studies (single dose)
- Repeat-dose toxicity studies (28-day, 90-day)
- Genotoxicity (Ames test, micronucleus assay)
- Reproductive toxicity
- Local tolerance studies
- Immunotoxicity assessment
- Pharmacokinetic/toxicokinetic correlation

### 3.4 Educational Taxonomy

#### 3.4.1 Knowledge Complexity Levels

**Level 1 — Foundational (High School / Early Undergraduate):**

- Basic amino acid structure and properties
- Definition and general properties of peptides
- Biological importance of peptides (hormones, antibiotics)
- Simplified structural representation (letter codes)
- Conceptual understanding of protein/peptide hierarchy

**Level 2 — Intermediate (Upper Undergraduate):**

- Peptide bond chemistry and stereochemistry
- Structural classification (primary, secondary, tertiary elements)
- Biosynthetic pathways (ribosomal basics)
- Receptor pharmacology fundamentals
- Introduction to structure-activity relationships
- Basic analytical methods (HPLC, MS introduction)

**Level 3 — Advanced (Graduate / Early Career Researcher):**

- Detailed conformational analysis (Ramachandran plots, NMR-derived structures)
- Non-ribosomal peptide synthesis mechanisms
- Receptor binding kinetics and signal transduction
- Advanced SAR studies and rational design
- Computational modeling approaches
- Manufacturing and formulation challenges
- Regulatory landscape

**Level 4 — Expert (Established Researcher / Specialist):**

- Cutting-edge computational peptide design (ML/AI-driven)
- Novel delivery systems and formulation science
- Clinical translation challenges and solutions
- Emerging therapeutic areas and pipeline analysis
- Methodological innovations in peptide characterization
- Cross-disciplinary integration (systems biology, synthetic biology)

#### 3.4.2 Learning Pathway Architecture

**encyclopeptide.com Approach:**

- Top-down information architecture: organized by peptide class, function, source
- Cross-referencing system: each monograph links to related peptides, receptors, pathways
- Progressive detail disclosure: summary → key data → full monograph → supplementary data
- Reference chain: abstract → citation → full text → supplementary materials

**wikipept.com Approach:**

- Bottom-up learning progression: foundational concepts → intermediate → advanced
- Interleaved review: spaced repetition across concept categories
- Active recall emphasis: quiz questions embedded within content
- Community scaffolding: learner-generated examples, explanations, mnemonics
- Mastery-based advancement: unlock advanced topics after demonstrating foundational competency

---

## 4. Audience Analysis

### 4.1 Primary Audience Segments

#### 4.1.1 Academic Researchers

**Profile:**

- Postdoctoral researchers, principal investigators, research scientists in biochemistry, pharmacology, medicinal chemistry, chemical biology
- Affiliations: universities, research institutes, pharmaceutical R&D, biotechnology companies
- Technical proficiency: expert to very advanced
- Primary tasks: literature review, data lookup, method selection, structural comparison, citation gathering
- Information needs: precise quantitative data, cited sources, reproducible structural information, current market/pipeline data

**Behavioral Patterns:**

- Direct URL access to specific peptide pages
- Database-style search queries (e.g., "angiotensin II receptor binding Ki")
- Structure-based navigation (searching by sequence, SMILES, or structural motif)
- Citation export for manuscripts
- Bulk data download for computational analysis
- Time-constrained: expect rapid access to specific data points

**Content Preferences:**

- Peer-reviewed references with DOIs
- Quantitative data tables with uncertainty estimates
- Structural diagrams in standard formats (PDB, SMILES, InChI)
- Methodological detail sufficient for experimental planning
- Minimal introductory content (skip to data)
- Multi-format data export (CSV, JSON, PDF)

**Pain Points:**

- Scattered data across multiple databases
- Inconsistent nomenclature across sources
- Difficulty finding specific parameter values buried in literature
- Time-consuming literature mining for systematic reviews
- Outdated data in traditional reference works

#### 4.1.2 Students (Undergraduate and Graduate)

**Profile:**

- Undergraduate biochemistry/biology/chemistry students (2nd–4th year)
- Graduate students in biochemistry, pharmacology, medicinal chemistry, chemical biology
- Medical students (preclinical years)
- Technical proficiency: beginner to intermediate (undergraduate), intermediate to advanced (graduate)
- Primary tasks: exam preparation, assignment completion, concept understanding, laboratory preparation
- Information needs: clear explanations, visual aids, worked examples, study guides, assessment tools

**Behavioral Patterns:**

- Topic-based navigation (searching for "peptide bond formation" or "glutathione function")
- Extended study sessions with progress tracking
- Use of flashcards and quiz features for memorization
- Peer collaboration and note-sharing
- Mobile access for study on-the-go
- Return visits to track learning progress

**Content Preferences:**

- Progressive complexity disclosure (overview → detail)
- Visual diagrams, animations, and 3D models
- Mnemonics and memory aids
- Practice questions with immediate feedback
- Comparison tables for similar concepts
- Real-world examples and clinical correlations

**Pain Points:**

- Overwhelming volume of information without clear learning path
- Difficulty connecting isolated facts into coherent understanding
- Lack of interactive assessment tools in traditional textbooks
- Inability to assess own mastery level
- Disconnect between exam content and available study materials

#### 4.1.3 Bioinformaticians and Computational Biologists

**Profile:**

- Bioinformatics analysts, computational biologists, structural bioinformaticians
- Software engineers working on biological data tools
- Data scientists in pharmaceutical/biotech contexts
- Technical proficiency: advanced to expert (domain-specific)
- Primary tasks: database queries, API integration, structural analysis, sequence analysis, data pipeline development
- Information needs: structured data, API documentation, data format specifications, version history, bulk access

**Behavioral Patterns:**

- API-first access patterns
- Bulk data download and parsing
- Programmatic search queries
- Cross-database integration
- Version tracking for reproducibility
- Minimal web UI interaction (prefer command-line/API)

**Content Preferences:**

- RESTful API with comprehensive documentation
- Standard data formats (FASTA, PDB, SDF, SMILES, JSON, XML)
- Bulk download endpoints
- Data schema documentation
- Versioning and changelog
- Machine-readable metadata

**Pain Points:**

- Inconsistent data formats across peptide databases
- Limited API access to curated peptide data
- Poor documentation of data provenance
- Difficulty integrating data from multiple sources
- Lack of standardized peptide identifiers

#### 4.1.4 General Public / Science Enthusiasts

**Profile:**

- Health-conscious individuals interested in supplements and bioactive peptides
- Science enthusiasts with non-professional interest
- Writers, journalists covering biotechnology topics
- Wellness industry professionals (nutritionists, naturopaths, fitness coaches)
- Technical proficiency: beginner to low-intermediate
- Primary tasks: concept exploration, term definitions, basic understanding of peptide-related topics
- Information needs: accessible explanations, context, reliability indicators, further reading suggestions

**Behavioral Patterns:**

- Natural language search queries (e.g., "what is glutathione good for")
- Reading introductory and overview content
- Limited use of technical features
- High bounce rate if content too technical
- Social sharing of accessible content

**Content Preferences:**

- Jargon-free language with glossary support
- Visual explanations (infographics, animations)
- Practical examples (dietary sources, supplement claims)
- Credibility indicators (peer-reviewed badges, expert authors)
- Links to deeper technical content for those who want to explore

**Pain Points:**

- Misinformation about peptide supplements and health claims
- Difficulty distinguishing evidence-based information from marketing
- Overly technical content in scientific sources
- Conflicting claims from different sources
- Lack of trusted, accessible reference material

### 4.2 Audience-Platform Mapping

| Audience Segment       | encyclopeptide.com Primary | encyclopeptide.com Secondary | wikipept.com Primary | wikipept.com Secondary |
| ---------------------- | -------------------------- | ---------------------------- | -------------------- | ---------------------- |
| Academic researchers   | ✓                          |                              |                      | ✓                      |
| Bioinformaticians      | ✓                          |                              |                      |                        |
| Graduate students      | ✓                          |                              | ✓                    |                        |
| Undergraduate students |                            | ✓                            | ✓                    |                        |
| Medical students       |                            | ✓                            | ✓                    |                        |
| General public         |                            |                              |                      | ✓                      |
| Science enthusiasts    |                            |                              | ✓                    |                        |
| Industry professionals | ✓                          |                              |                      |                        |

### 4.3 User Journey Mapping

#### 4.3.1 encyclopeptide.com — Researcher Journey

```
Entry (search/URL) → Specific peptide page → Key data overview
    ├── Structure viewer (3D exploration)
    ├── Synthesis route diagram
    ├── Receptor binding data table
    ├── Pharmacokinetic parameters
    ├── Literature references (DOI-linked)
    ├── Related peptides (cross-reference)
    └── Export (CSV, JSON, citation format)
```

#### 4.3.2 wikipept.com — Student Journey

```
Entry (search/referral) → Topic landing page → Foundational overview
    ├── Read concept explanation (progressive depth)
    ├── Watch animation/interactive demo
    ├── Take practice quiz (immediate feedback)
    ├── Review flashcards (spaced repetition scheduling)
    ├── Explore community annotations
    ├── Compare with related concepts (comparison table)
    ├── Check progress dashboard
    └── Unlock next topic (mastery-gated)
```

---

## 5. Content Strategy Distinction Matrix

### 5.1 Content Type Comparison

| Content Dimension     | encyclopeptide.com                             | wikipept.com                                                      |
| --------------------- | ---------------------------------------------- | ----------------------------------------------------------------- |
| **Tone**              | Formal, academic, authoritative                | Conversational, supportive, community-oriented                    |
| **Voice**             | Third-person, passive constructions common     | Second-person active, encouraging                                 |
| **Citation model**    | DOI-linked, numbered references, journal-style | Inline hyperlinks, community annotations, "learn more" links      |
| **Update frequency**  | Periodic (quarterly/annual major updates)      | Continuous (real-time community edits)                            |
| **Editorial review**  | Expert editorial board, peer review process    | Community moderation, expert oversight, reputation-weighted trust |
| **Structural format** | Monographs, data tables, structured profiles   | Tutorials, study guides, wikis, quizzes, flashcards               |
| **Visual style**      | Minimal, data-dense, precise                   | Rich, illustrative, approachable                                  |
| **Error handling**    | Corrections issued as errata, versioned        | Edit history, community corrections, flagged disputes             |

### 5.2 Visual Identity Specification

#### 5.2.1 encyclopeptide.com Design System

**Color Palette:**

- Primary: Dark Navy (#1B2A4A) — authority, depth, scientific rigor
- Secondary: White (#FFFFFF) — clarity, readability, clinical precision
- Accent: Gold (#C9A84C) — prestige, scholarly distinction, premium quality
- Supporting neutrals: Light Gray (#F5F5F5), Medium Gray (#E0E0E0), Charcoal (#333333)
- Data visualization: sequential blue-to-navy gradient, categorical distinct palette
- Alert colors: Deep Red (#B71C1C) for warnings, Forest Green (#1B5E20) for confirmations

**Typography:**

- Headings: Playfair Display (serif) — elegance, tradition, academic authority
  - H1: 36px, weight 700, letter-spacing -0.02em
  - H2: 28px, weight 600, letter-spacing -0.01em
  - H3: 22px, weight 600
- Body text: Inter (sans-serif) — clarity, readability, modern precision
  - Body: 16px, weight 400, line-height 1.7
  - Small: 14px, weight 400, line-height 1.6
  - Caption: 12px, weight 400, line-height 1.5
- Monospace: JetBrains Mono — for sequences, code, SMILES notation
  - Code: 14px, weight 400

**Layout Principles:**

- Maximum content width: 960px (optimal line length for academic reading)
- Generous whitespace: 24px minimum between sections
- Grid system: 12-column with 16px gutter
- Card style: no rounded corners, 1px solid border, subtle shadow
- Navigation: fixed left sidebar with collapsible sections
- Data tables: full-width, sortable, with filter controls
- Molecular viewer: prominent, full-width on relevant pages

**Component Design:**

- Buttons: minimal, rectangular, no rounded corners, thin borders
- Forms: clean, fieldset-grouped, inline validation
- Alerts: left-bordered, no icons, muted tones
- Modals: minimal animation, centered, no backdrop blur
- Breadcrumbs: visible, hierarchical, clickable at each level
- Tabs: underlined active indicator, no fill
- Tags: small, uppercase, letter-spaced

#### 5.2.2 wikipept.com Design System

**Color Palette:**

- Primary: Teal (#0097A7) — learning, growth, approachability
- Secondary: White (#FFFFFF) — openness, clarity
- Accent: Coral (#FF6F61) — energy, engagement, warmth
- Supporting neutrals: Warm Gray (#F8F6F3), Light Teal (#E0F7FA), Cream (#FFFDE7)
- Success: Mint Green (#66BB6A)
- Warning: Amber (#FFC107)
- Error: Coral Red (#EF5350)
- Community badge colors: Gold (#FFD54F), Silver (#B0BEC5), Bronze (#D7CCC8)

**Typography:**

- Headings: Inter (sans-serif) — modern, friendly, approachable
  - H1: 32px, weight 700, letter-spacing -0.01em
  - H2: 26px, weight 600
  - H3: 20px, weight 600
- Body text: Inter (sans-serif) — consistency, readability
  - Body: 16px, weight 400, line-height 1.75
  - Small: 14px, weight 400, line-height 1.65
  - Caption: 12px, weight 400, line-height 1.5
- Monospace: JetBrains Mono — for sequences, code
  - Code: 14px, weight 400

**Layout Principles:**

- Maximum content width: 720px (focused reading experience)
- Card-based layout: 16px border-radius, 8px padding, subtle shadow (0 2px 8px rgba(0,0,0,0.08))
- Grid system: responsive flexbox/grid, mobile-first
- Navigation: top header with dropdown menus, optional right sidebar for progress
- Community features: avatar displays, contribution badges, reputation scores
- Interactive elements: prominent quiz/flashcard launch buttons
- Progress indicators: visual progress bars, streak counters, mastery badges

**Component Design:**

- Buttons: 8px border-radius, solid fills, hover elevation
- Cards: rounded corners, hover shadow, click feedback
- Alerts: rounded, icon-inclusive, colored backgrounds (10% opacity)
- Modals: smooth entrance animation, rounded, backdrop blur
- Breadcrumbs: pill-styled, colored active state
- Tabs: filled active indicator, rounded
- Tags: rounded pills, colored backgrounds
- Progress bars: rounded, gradient fills
- Avatars: circular, with online indicator
- Tooltips: rounded, subtle shadow, delayed appearance

### 5.3 Content Structure Templates

#### 5.3.1 encyclopeptide.com — Oligopeptide Monograph Template

```markdown
# [Peptide Name] (IUPAC: [Full IUPAC Name])

## Classification

- **Chain Length:** [X] residues
- **Chemical Class:** [Linear/Cyclic/Branched]
- **Functional Category:** [Primary category]
- **Source Organism(s):** [List]
- **CAS Registry Number:** [Number]
- **UniProt ID:** [ID] (if applicable)
- **PDB Entries:** [List of PDB IDs]

## Structural Information

### Primary Sequence

[Single-letter amino acid sequence, N→C]
[3-letter sequence notation]
[Molecular formula]
[Molecular weight: X.XX Da]
[Net charge at pH 7.4: ±X]

### Structural Features

[Description of key structural elements]
[Disulfide bond pattern, if applicable]
[Post-translational modifications]
[Conformational preferences]

### 3D Structure

[Interactive 3D viewer: Mol*/NGL]
[PDB source(s)]
[Key structural measurements]

## Biological Activity

### Target Receptors

| Receptor        | Affinity  | Method       | Reference |
| --------------- | --------- | ------------ | --------- |
| [Receptor name] | Kd = X nM | [Assay type] | [DOI]     |

### Physiological Function

[Detailed description of biological role]
[Signaling pathways involved]
[Downstream effects]

### Biosynthesis

[Biosynthetic pathway]
[Precursor processing]
[Enzymes involved]

## Pharmacological Properties

### Pharmacokinetic Parameters

| Parameter | Value       | Species   | Route   | Reference |
| --------- | ----------- | --------- | ------- | --------- |
| t₁/₂      | X hr        | [Species] | [Route] | [DOI]     |
| F         | X%          | [Species] | [Route] | [DOI]     |
| Vd        | X L/kg      | [Species] | [Route] | [DOI]     |
| CL        | X mL/min/kg | [Species] | [Route] | [DOI]     |

### Therapeutic Applications

[Current clinical uses]
[Investigational uses]
[Clinical trial status]

### Safety Profile

[Known adverse effects]
[Contraindications]
[Drug interactions]

## Synthesis

### Chemical Synthesis

[SPPS route details]
[Coupling strategy]
[Protected resin choice]
[Cleavage conditions]
[Yield and purity]

### Biosynthetic Production

[Expression system]
[Upstream processing]
[Downstream purification]
[Scalability considerations]

## Analytical Characterization

### Mass Spectrometry

[Expected m/z values]
[Fragmentation pattern]

### HPLC

[Retention time conditions]
[Purity specification]

### NMR

[Key diagnostic signals]
[Conformational indicators]

## History and Discovery

[Discovery timeline]
[Key researchers]
[Nobel Prize connections, if applicable]

## References

1. [Author(s)]. [Title]. _Journal_ **Volume**, Pages (Year). DOI: [DOI]
2. ...

## Related Peptides

- [Peptide A]: [Brief relationship description]
- [Peptide B]: [Brief relationship description]

## External Links

- [UniProt](link)
- [PDB](link)
- [ChEMBL](link)
- [DrugBank](link)
```

#### 5.3.2 wikipept.com — Study Guide Template

```markdown
# [Concept/Topic Name]

## Overview

[2-3 sentence summary in plain language]

**Prerequisites:** [List of concepts you should know first]
**Estimated study time:** [X minutes]
**Difficulty level:** ⭐⭐☆☆☆ (Beginner) / ⭐⭐⭐☆☆ (Intermediate) / ⭐⭐⭐⭐☆ (Advanced) / ⭐⭐⭐⭐⭐ (Expert)

---

## What You'll Learn

- [ ] [Learning objective 1]
- [ ] [Learning objective 2]
- [ ] [Learning objective 3]

---

## The Basics

[Simple, intuitive explanation with analogies]

> 💡 **Memory Aid:** [Mnemonic or memory trick]

---

## Going Deeper

[Intermediate-level detail with connections to related concepts]

### Key Terms

| Term   | Definition                  | Example            |
| ------ | --------------------------- | ------------------ |
| [Term] | [Plain language definition] | [Concrete example] |

---

## Expert Level

[Advanced detail, current research frontiers]

---

## Check Your Understanding

### Quiz

1. [Multiple choice question]
   - a) ...
   - b) ...
   - c) ...
   - d) ...
   - **Answer:** [X] — [Brief explanation]

2. [Fill-in-the-blank question]
   - **Answer:** ...

### Flashcards

[Auto-generated flashcards from key terms]

---

## Community Notes

[Community-contributed annotations, tips, and clarifications]
[Version history for edits]

---

## Connections

- **Builds on:** [Previous concepts]
- **Leads to:** [Next concepts]
- **Related to:** [Parallel concepts]

---

## Further Reading

- [Accessible article] — [Brief description]
- [Intermediate resource] — [Brief description]
- [Advanced paper] — [Brief description]

---

**Last updated:** [Date] by [Contributor]
**Quality rating:** ⭐⭐⭐⭐☆ (4.2/5 from 47 reviews)
```

### 5.4 Metadata and Structured Data

#### 5.4.1 encyclopeptide.com Schema

```json
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "name": "Angiotensin II",
  "alternateName": ["Ang II", "Angiotensin II octapeptide"],
  "description": "Comprehensive monograph on angiotensin II oligopeptide",
  "identifier": {
    "@type": "PropertyValue",
    "propertyID": "Peptide ID",
    "value": "ENCP-00001"
  },
  "classification": {
    "chainLength": 8,
    "chemicalClass": "Linear",
    "functionalCategory": "Hormonal regulator",
    "sourceOrganism": "Homo sapiens"
  },
  "isPartOf": {
    "@type": "WebSite",
    "name": "Encyclopeptide",
    "url": "https://encyclopeptide.com"
  },
  "citation": [...],
  "keywords": ["angiotensin", "octapeptide", "RAAS", "hypertension"]
}
```

#### 5.4.2 wikipept.com Schema

```json
{
  "@context": "https://schema.org",
  "@type": "LearningResource",
  "name": "Understanding Peptide Bonds",
  "description": "Interactive study guide on peptide bond chemistry",
  "educationalLevel": "Intermediate",
  "learningResourceType": "Study Guide",
  "timeRequired": "PT20M",
  "assesses": ["Peptide bond structure", "Resonance stabilization"],
  "teaches": ["Peptide bond formation", "Peptide bond properties"],
  "prerequisite": ["Amino acid structure"],
  "isPartOf": {
    "@type": "Course",
    "name": "Oligopeptide Fundamentals",
    "provider": {
      "@type": "Organization",
      "name": "Wikipept"
    }
  },
  "interactionStatistic": [
    {
      "@type": "InteractionCounter",
      "interactionType": "https://schema.org/Quiz",
      "userInteractionCount": 1247
    }
  ],
  "aggregateRating": {
    "@type": "AggregateRating",
    "ratingValue": 4.3,
    "ratingCount": 89
  }
}
```

---

## 6. Technical Domain Constraints

### 6.1 Data Integrity Requirements

#### 6.1.1 Accuracy Standards

**encyclopeptide.com:**

- All quantitative values must cite primary literature with DOI
- Structural data must cross-reference PDB, UniProt, or ChEMBL
- Molecular weights must be calculated from verified sequences
- Pharmacokinetic parameters must specify species, route, and study design
- Error bars or confidence intervals required where data permits
- Nomenclature must conform to IUPAC-IUB Joint Commission standards
- Regular data audit cycle (minimum annual review)

**wikipept.com:**

- Factual claims must be verifiable via cited references
- Community edits must be attributed and version-controlled
- Expert-reviewed content must be flagged with review date and reviewer credentials
- Educational content must be validated against current scientific consensus
- Community annotations must be moderated for accuracy
- Misinformation flagging system with rapid response protocol

#### 6.1.2 Completeness Metrics

| Metric                                    | encyclopeptide.com Target           | wikipept.com Target             |
| ----------------------------------------- | ----------------------------------- | ------------------------------- |
| Coverage of known bioactive oligopeptides | ≥80% of entries in major databases  | Key 500 peptides (curated)      |
| Structural data availability              | ≥90% have PDB or computed structure | ≥70% have visual representation |
| Reference coverage                        | Every data point cited              | Every section has ≥3 references |
| Cross-reference density                   | ≥5 internal links per monograph     | ≥3 internal links per guide     |
| Update recency                            | ≤12 months for any monograph        | ≤6 months for popular topics    |

### 6.2 Performance Requirements

#### 6.2.1 Page Load Performance

| Metric                         | Target                | Measurement                 |
| ------------------------------ | --------------------- | --------------------------- |
| First Contentful Paint (FCP)   | <1.5s                 | Lighthouse, 75th percentile |
| Largest Contentful Paint (LCP) | <2.5s                 | Lighthouse, 75th percentile |
| Cumulative Layout Shift (CLS)  | <0.1                  | Lighthouse, 75th percentile |
| First Input Delay (FID)        | <100ms                | Lighthouse, 75th percentile |
| Time to Interactive (TTI)      | <3.5s                 | Lighthouse, 75th percentile |
| Total page weight              | <500KB (initial load) | Webpack analysis            |

#### 6.2.2 3D Molecular Viewer Performance

| Metric                            | Target                            |
| --------------------------------- | --------------------------------- |
| Initial viewer load               | <2s (with lazy loading)           |
| Rotation/zoom responsiveness      | 60fps                             |
| Large structure (>100 atoms) load | <3s                               |
| Memory usage                      | <500MB per viewer instance        |
| Mobile compatibility              | Touch gestures, responsive sizing |

#### 6.2.3 Database Query Performance

| Metric                           | Target                     |
| -------------------------------- | -------------------------- |
| Simple search response           | <200ms                     |
| Complex filtered search          | <500ms                     |
| API response time (p95)          | <300ms                     |
| Database connection pool         | Configurable, auto-scaling |
| Full-text search index freshness | <1 hour for new content    |

### 6.3 Accessibility Requirements

#### 6.3.1 WCAG 2.1 Compliance

**Level AA (mandatory):**

- All text meets 4.5:1 contrast ratio (normal text), 3:1 (large text)
- All interactive elements keyboard-accessible
- All images have alt text (including molecular visualizations)
- Page structure uses semantic HTML (headings, landmarks, lists)
- Forms have associated labels and error messages
- Skip navigation links provided
- Focus indicators visible on all interactive elements
- Motion can be paused or disabled

**Level AAA (aspirational):**

- 7:1 contrast ratio for critical content
- Sign language interpretation for video content
- Extended audio description for visual content
- Reading level indicators for educational content

#### 6.3.2 Molecular Viewer Accessibility

- Alternative 2D structural representation for all 3D models
- Text description of key structural features
- Keyboard-only rotation/zoom controls
- Screen reader-compatible atom/bond information
- High-contrast mode for structural diagrams
- Color-blind safe color schemes for structural visualization

### 6.4 Security Requirements

#### 6.4.1 Data Protection

- HTTPS enforced for all pages (HSTS with preload)
- Content Security Policy (CSP) headers configured
- API rate limiting per IP/authenticated user
- Input validation and sanitization for all user inputs
- SQL injection prevention via parameterized queries
- XSS prevention via output encoding and CSP
- CSRF protection via tokens

#### 6.4.2 User Account Security (wikipept.com)

- Password hashing via bcrypt/argon2 with salt
- Multi-factor authentication support
- OAuth 2.0 / OpenID Connect integration
- Account lockout after failed attempts
- Session management with secure, HttpOnly cookies
- Email verification for new accounts
- GDPR/CCPA compliance for user data

### 6.5 Scalability Requirements

#### 6.5.1 Traffic Projections

| Metric                                       | Year 1 | Year 3 | Year 5 |
| -------------------------------------------- | ------ | ------ | ------ |
| Monthly unique visitors (encyclopeptide.com) | 50K    | 200K   | 500K   |
| Monthly unique visitors (wikipept.com)       | 100K   | 500K   | 1.5M   |
| Concurrent users (peak)                      | 500    | 2,000  | 5,000  |
| API requests/day                             | 10K    | 100K   | 500K   |
| Storage growth (content)                     | 10GB   | 50GB   | 150GB  |
| Storage growth (user data)                   | 5GB    | 30GB   | 100GB  |

#### 6.5.2 Architecture Considerations

- CDN for static asset delivery (global edge locations)
- Database read replicas for query scaling
- Cache layer (Redis/Memcached) for frequent queries
- Background job queue for search index updates
- Horizontal scaling capability for application servers
- Database sharding strategy for long-term growth
- Microservice decomposition for independent scaling of:
  - Content management
  - Search and indexing
  - User authentication
  - Quiz/flashcard engine
  - Analytics and progress tracking

### 6.6 Integration Constraints

#### 6.6.1 External API Dependencies

| Service     | Purpose               | Rate Limits         | Fallback Strategy          |
| ----------- | --------------------- | ------------------- | -------------------------- |
| UniProt API | Protein/peptide data  | 100 req/sec         | Cached data, local mirror  |
| PDB API     | Structural data       | 200 req/sec         | Cached structures          |
| ChEMBL API  | Bioactivity data      | 50 req/sec          | Pre-cached popular entries |
| PubMed API  | Literature search     | 3 req/sec (API key) | Cached results             |
| ORCID API   | Author identification | 100 req/sec         | Manual entry               |

#### 6.6.2 Third-Party Service Dependencies

- Analytics: privacy-respecting (Plausible, Fathom, or self-hosted Matomo)
- Email: transactional email service (Postmark, SendGrid)
- Hosting: CDN + static hosting (Cloudflare Pages, Vercel, Netlify)
- Search: Meilisearch, Typesense, or Elasticsearch
- Monitoring: uptime monitoring, error tracking (Sentry)

### 6.7 Content Management Requirements

#### 6.7.1 encyclopeptide.com CMS

- Git-based content management (MDX/markdown files in repository)
- Structured data templates enforced at schema level
- Editorial workflow: draft → review → approve → publish
- Version control with diff visualization for content changes
- Automated link checking for DOI validity
- Structured data validation on commit
- Preview environment for draft content

#### 6.7.2 wikipept.com CMS

- Wiki-style editing interface (block-based or markdown)
- Real-time collaborative editing (optional, with operational transform)
- Version history with rollback capability
- Edit conflict resolution
- Community moderation queue
- Content flagging and dispute resolution workflow
- Template system for consistent page structures
- Category and tag management for content organization

---

## 7. Risk Assessment

### 7.1 Technical Risks

#### 7.1.1 3D Molecular Viewer Integration

**Risk Level:** HIGH

**Description:** Integrating web-based 3D molecular viewers (Mol\*, NGL Viewer, 3Dmol.js) with reliable performance across devices and browsers presents significant technical challenges.

**Impact:**

- Broken visualization on mobile devices or older browsers
- Performance degradation with large molecular structures
- Inconsistent rendering across WebGL implementations
- Accessibility gaps for screen reader users

**Mitigation:**

- Progressive enhancement: provide 2D fallback for all 3D content
- Lazy loading for viewer initialization
- Structure simplification algorithms for mobile
- Cross-browser testing matrix (Chrome, Firefox, Safari, Edge, mobile browsers)
- Accessibility audit specific to viewer components
- Performance budget enforcement per page

**Residual Risk:** Medium — WebGL compatibility remains partially unpredictable across hardware configurations.

#### 7.1.2 Search Performance at Scale

**Risk Level:** MEDIUM

**Description:** Full-text search across thousands of oligopeptide monographs with complex filtering (by sequence, property, receptor, etc.) may degrade as content grows.

**Impact:**

- Slow search response times (>500ms) frustrating researchers
- Incomplete or inaccurate search results
- High infrastructure costs for search infrastructure

**Mitigation:**

- Implement Meilisearch/Typesense for instant search
- Pre-compute common filter combinations
- Search result caching for popular queries
- Regular search quality audits
- Pagination and infinite scroll for result sets
- Search analytics to identify optimization opportunities

**Residual Risk:** Low — proven search technologies with established scaling patterns.

#### 7.1.3 Data Synchronization Across Platforms

**Risk Level:** MEDIUM

**Description:** Both sites share underlying peptide data, but present it differently. Keeping data synchronized while allowing independent content evolution is challenging.

**Impact:**

- Data inconsistencies between platforms
- Double maintenance burden for core data
- Version conflicts when content is updated independently

**Mitigation:**

- Shared data layer (API/database) with independent presentation layers
- Clear data ownership model: canonical data vs. platform-specific annotations
- Automated consistency checks between platforms
- Synchronization audit reports

**Residual Risk:** Low — manageable with proper architectural separation.

#### 7.1.4 Mobile Performance of Interactive Features

**Risk Level:** MEDIUM

**Description:** Quizzes, flashcards, spaced repetition, and progress tracking must perform well on mobile devices with limited compute and memory.

**Impact:**

- Sluggish quiz experience on low-end devices
- Spaced repetition scheduling errors if offline sync fails
- Battery drain from background progress sync

**Mitigation:**

- Offline-first architecture for learning features
- Local-first data storage with periodic sync
- Lightweight quiz engine optimized for mobile
- Service worker for offline access to downloaded content
- Battery-aware sync scheduling

**Residual Risk:** Low — established mobile-first development patterns available.

### 7.2 Content Risks

#### 7.2.1 Scientific Accuracy and Currency

**Risk Level:** HIGH

**Description:** The rapidly evolving nature of peptide science means content can become outdated, and errors in scientific data can have serious consequences for research and education.

**Impact:**

- Researchers making decisions based on outdated pharmacokinetic data
- Students learning incorrect mechanisms or structures
- Loss of credibility if errors are publicly identified
- Legal liability if clinical decisions are influenced by inaccurate data

**Mitigation:**

- Mandatory citation requirements for all quantitative claims
- Regular content review cycle (minimum annual for all monographs)
- Community reporting mechanism for errors
- Expert reviewer network for content validation
- Prominent "last reviewed" and "next scheduled review" dates
- Version control with audit trail for all changes
- Clear disclaimer: reference resource, not clinical guidance
- Rapid correction protocol with errata publication

**Residual Risk:** Medium — human review processes cannot guarantee zero errors.

#### 7.2.2 Community Content Quality (wikipept.com)

**Risk Level:** HIGH

**Description:** Wiki-style collaborative editing introduces risk of misinformation, vandalism, or low-quality contributions degrading educational value.

**Impact:**

- Students learning incorrect information from community edits
- Vandalism or spam content appearing on educational pages
- Expert contributors leaving if quality standards are not maintained
- Reputational damage from high-profile errors

**Mitigation:**

- Reputation-weighted trust system (experienced contributors have higher edit priority)
- Expert review queue for edits to high-traffic pages
- Automated quality checks (citation requirements, formatting standards)
- Community moderation tools (flag, vote, revert)
- "Pending changes" review for new contributors -定期 expert review of all educational content
- Clear community guidelines and code of conduct
- Escalation path for disputed content

**Residual Risk:** Medium — community dynamics are inherently unpredictable.

#### 7.2.3 Intellectual Property and Licensing

**Risk Level:** MEDIUM

**Description:** Oligopeptide data may be subject to database rights, copyright on curated data, or patent restrictions on specific therapeutic information.

**Impact:**

- Legal challenges from data providers
- Restrictions on data redistribution
- Licensing fee requirements
- Geographic limitations on content availability

**Mitigation:**

- Clear licensing model for all content (Creative Commons for educational, fair use for reference)
- Original data compilation and curation (not direct database copying)
- Legal review of data sourcing practices
- Respect for robots.txt and API terms of service
- Attribution requirements clearly stated and enforced
- Patent landscape monitoring for therapeutic content

**Residual Risk:** Low — with proper legal review and licensing compliance.

### 7.3 User Experience Risks

#### 7.3.1 Information Architecture Complexity

**Risk Level:** MEDIUM

**Description:** The vast dimensionality of oligopeptide classification (by length, function, source, structure, application) creates navigation challenges.

**Impact:**

- Users unable to find specific peptide information
- Overwhelming choice architecture leading to decision paralysis
- Inconsistent navigation patterns across content categories
- Deep content hierarchies burying important information

**Mitigation:**

- Multi-axis faceted navigation system
- Prominent search with auto-suggest
- Popular/recent content highlighting
- Breadcrumb navigation on all pages
- Sitemap with visual hierarchy
- User testing of navigation patterns before launch
- Analytics-driven iterative improvement

**Residual Risk:** Low — with iterative UX refinement.

#### 7.3.2 Learning Curve for Interactive Features

**Risk Level:** LOW

**Description:** Advanced features (flashcards, spaced repetition, progress tracking) require user education to maximize value.

**Impact:**

- Users underutilizing valuable features
- Frustration with complex onboarding
- Higher bounce rate for new users

**Mitigation:**

- Progressive feature disclosure (introduce features contextually)
- Interactive tutorial/walkthrough for new users
- Tooltips and contextual help
- Template-based quick start for common use cases
- Video demonstrations of key features
- Community forums for peer support

**Residual Risk:** Low — standard UX onboarding patterns.

### 7.4 Operational Risks

#### 7.4.1 Data Backup and Disaster Recovery

**Risk Level:** MEDIUM

**Description:** Loss of content data (especially community contributions and user progress) could be catastrophic.

**Impact:**

- Loss of community-contributed content and annotations
- Loss of user learning progress and flashcard decks
- Extended downtime during recovery
- Loss of user trust

**Mitigation:**

- Automated daily backups with off-site storage
- Database point-in-time recovery capability
- Annual disaster recovery drill
- Recovery Time Objective (RTO): 4 hours
- Recovery Point Objective (RPO): 1 hour
- User-facing backup/export functionality
- Redundant infrastructure across availability zones

**Residual Risk:** Low — established backup and DR practices.

#### 7.4.2 Scalability Under Unexpected Traffic

**Risk Level:** MEDIUM

**Description:** Viral content, media coverage, or academic adoption could cause traffic spikes exceeding capacity.

**Impact:**

- Site unavailability during peak demand
- Degraded performance for all users
- Lost revenue and reputation damage

**Mitigation:**

- Auto-scaling infrastructure (cloud-native)
- CDN caching for static content
- Database query caching and read replicas
- Rate limiting and queue management
- Load testing prior to launch (target 10x expected peak)
- Incident response playbook
- Status page for transparency during incidents

**Residual Risk:** Low — with proper cloud architecture.

#### 7.4.3 Dependency and Supply Chain Security

**Risk Level:** MEDIUM

**Description:** Third-party dependencies (npm packages, CDN services, external APIs) may introduce vulnerabilities.

**Impact:**

- Security breaches via compromised dependencies
- Service disruption from third-party outages
- Legal liability from data breaches

**Mitigation:**

- Dependency scanning (Snyk, Dependabot, npm audit)
- Lock file pinning for all dependencies
- Regular dependency updates with testing
- Vendor risk assessment for critical services
- Fallback mechanisms for critical external APIs
- Content Security Policy to limit third-party script execution
- Regular security audits and penetration testing

**Residual Risk:** Low — with proactive dependency management.

### 7.5 Risk Matrix Summary

| Risk Category | Risk                   | Likelihood | Impact | Overall  | Mitigation Priority |
| ------------- | ---------------------- | ---------- | ------ | -------- | ------------------- |
| Technical     | 3D viewer integration  | High       | Medium | HIGH     | P0                  |
| Technical     | Search at scale        | Medium     | Medium | MEDIUM   | P1                  |
| Technical     | Data sync              | Medium     | Low    | LOW      | P2                  |
| Technical     | Mobile performance     | Medium     | Medium | MEDIUM   | P1                  |
| Content       | Scientific accuracy    | High       | High   | CRITICAL | P0                  |
| Content       | Community quality      | High       | High   | CRITICAL | P0                  |
| Content       | IP/licensing           | Medium     | Medium | MEDIUM   | P1                  |
| UX            | Info architecture      | Medium     | Medium | MEDIUM   | P1                  |
| UX            | Feature learning curve | Low        | Low    | LOW      | P2                  |
| Operational   | Backup/recovery        | Medium     | High   | HIGH     | P0                  |
| Operational   | Traffic scaling        | Medium     | Medium | MEDIUM   | P1                  |
| Operational   | Supply chain           | Medium     | Medium | MEDIUM   | P1                  |

---

## 8. Multi-lingual Requirements

### 8.1 Language Priority and Scope

#### 8.1.1 Primary Language

**English (EN)** — All content initially created and maintained in English.

- All monographs, study guides, and interactive content authored in English
- English serves as the canonical source language for translation
- Scientific nomenclature, chemical formulas, and technical notation remain in English/IUPAC standard regardless of display language
- All user interface elements, navigation, and system messages in English as baseline

#### 8.1.2 Secondary Languages (Phase 2+)

| Language             | Code  | Priority | Estimated Coverage Target | Key Markets                                 |
| -------------------- | ----- | -------- | ------------------------- | ------------------------------------------- |
| Chinese (Simplified) | ZH-CN | High     | 80% of core content       | Mainland China, Singapore, Taiwan           |
| Russian              | RU    | High     | 60% of core content       | Russia, CIS countries                       |
| German               | DE    | Medium   | 60% of core content       | Germany, Austria, Switzerland               |
| French               | FR    | Medium   | 60% of core content       | France, Canada, Belgium, Francophone Africa |
| Japanese             | JP    | Medium   | 60% of core content       | Japan                                       |

### 8.2 Localization Requirements

#### 8.2.1 Content Translation Strategy

**Translation Approach per Content Type:**

| Content Type            | encyclopeptide.com                           | wikipept.com                          |
| ----------------------- | -------------------------------------------- | ------------------------------------- |
| Oligopeptide monographs | Full professional translation                | Professional + community review       |
| Study guides            | Full professional translation                | Community translation + expert review |
| Quiz questions          | Full professional translation                | Community translation + validation    |
| Flashcards              | Professional (core) + community (expansions) | Community translation + validation    |
| UI elements             | Full professional translation                | Full professional translation         |
| Navigation              | Full professional translation                | Full professional translation         |
| Help documentation      | Full professional translation                | Full professional translation         |
| Community contributions | N/A (no community edits)                     | Community-contributed (with review)   |

#### 8.2.2 Scientific Nomenclature Handling

**Rules for multi-lingual scientific content:**

1. **IUPAC nomenclature** remains in English/IUPAC standard regardless of display language
2. **Amino acid names** use internationally recognized 3-letter and 1-letter codes
3. **Chemical formulas** use standard notation (H₂O, not localized)
4. **Gene and protein symbols** follow HGNC/UniProt nomenclature (language-independent)
5. **Structural diagrams** use universally understood conventions
6. **Units** follow SI standard (nm, Da, M, etc.)
7. **Numerical values** use locale-appropriate formatting (decimal separator, thousands separator)
8. **Peptide sequences** always written N→C in single-letter code regardless of language

**Language-Specific Adaptations:**

- Common names may use localized versions where established (e.g., Chinese: 谷胱甘肽 for glutathione)
- Transliteration systems for non-Latin scripts must follow IUPAC recommendations
- Untranslated technical terms marked with `<notranslate>` tag
- Glossary of standardized translations for recurring terms per language

#### 8.2.3 Content Metadata Localization

Each localized page must include:

- Language-specific `<title>` and `<meta description>`
- `hreflang` tags for all language versions of each page
- Language-specific Open Graph and social media metadata
- Structured data in the page language with `inLanguage` property
- Last translation review date
- Translator attribution (for professional translations)
- Community review status (for community-translated content)

### 8.3 Technical Localization

#### 8.3.1 Internationalization (i18n) Architecture

**Frontend:**

- Framework-level i18n support (next-intl, react-intl, or equivalent)
- Translation files in JSON/PO format per language
- Namespace-based translation organization (common, navigation, content-type-specific)
- Dynamic language switching without page reload
- URL structure: `example.com/en/peptide/angiotensin-ii` or `example.com/zh/peptide/angiotensin-ii`

**Backend:**

- UTF-8 encoding throughout
- Locale-aware sorting and collation in database
- Date/time formatting per locale
- Number formatting per locale (decimal point, thousands separator)
- Currency formatting (where applicable, e.g., for commercial features)
- Right-to-left (RTL) support preparation (not needed for current language list, but architecture should accommodate future Arabic, Hebrew support)

#### 8.3.2 URL and Routing Structure

```
encyclopeptide.com/
├── /en/angiotensin-ii          (English)
├── /zh/angiotensin-ii          (Chinese)
├── /ru/angiotensin-ii          (Russian)
├── /de/angiotensin-ii          (German)
├── /fr/angiotensin-ii          (French)
├── /jp/angiotensin-ii          (Japanese)
```

**Routing rules:**

- Default language (EN) can be accessed without language prefix: `/angiotensin-ii` redirects to `/en/angiotensin-ii`
- All other languages require explicit prefix
- Language prefix detection and auto-redirect based on `Accept-Language` header (first visit only)
- User language preference persisted in cookie/localStorage
- Language switcher prominently available on all pages

#### 8.3.3 Search Localization

- Language-specific search indices per language
- Search queries processed in the current page language
- Cross-language search option (search English content from Chinese interface)
- Translated search suggestions and auto-complete
- Language-aware synonym mapping (e.g., "peptide" ↔ "肽" ↔ "пептид")

### 8.4 Translation Workflow

#### 8.4.1 Professional Translation Pipeline

**Step 1: Content Freeze**

- English content marked as "ready for translation"
- Translation memory updated with current source text
- Glossary terms verified and updated

**Step 2: Translation**

- Professional translators with domain expertise (biochemistry/pharmacology)
- Translation memory leverage (TM match scoring)
- Machine translation post-editing (MTPE) for efficiency on large volumes
- Glossary compliance check

**Step 3: Review**

- Bilingual review by second translator
- Technical accuracy review by domain expert (same language)
- Terminology consistency check
- Formatting and markup validation

**Step 4: Integration**

- Translated content integrated into CMS
- Automated quality checks (missing tags, broken links, formatting)
- Preview and QA by content team
- Publication

#### 8.4.2 Community Translation (wikipept.com)

**Contribution Flow:**

1. Contributor selects untranslated or outdated page
2. Translation editor displays source (EN) alongside target language
3. Contributor translates inline, with glossary suggestions
4. Submitted for community review (minimum 2 reviewers)
5. Expert validation for technical accuracy (for flagged content)
6. Publication upon approval

**Quality Controls:**

- Minimum contributor reputation score for translation submissions
- Automated glossary compliance checking
- Translation memory consistency checks
- Plagiarism detection against existing translations
- Periodic expert audit of community translations

### 8.5 Glossary Management

#### 8.5.1 Core Terminology Table

| English                         | Chinese (ZH) | Russian (RU)                     | German (DE)                   | French (FR)                 | Japanese (JP)        |
| ------------------------------- | ------------ | -------------------------------- | ----------------------------- | --------------------------- | -------------------- |
| Oligopeptide                    | 寡肽         | олигопептид                      | Oligopeptid                   | Oligopeptide                | オリゴペプチド       |
| Peptide bond                    | 肽键         | пептидная связь                  | Peptidbindung                 | Liaison peptidique          | ペプチド結合         |
| Amino acid                      | 氨基酸       | аминокислота                     | Aminosäure                    | Acide aminé                 | アミノ酸             |
| Structure-activity relationship | 构效关系     | соотношение структура-активность | Struktur-Aktivitäts-Beziehung | Relation structure-activité | 構造活性相関         |
| Pharmacokinetics                | 药代动力学   | фармакокинетика                  | Pharmakokinetik               | Pharmacocinétique           | ファマコキネティクス |
| Receptor binding                | 受体结合     | связывание с рецептором          | Rezeptorbindung               | Liaison au récepteur        | 受容体結合           |
| Solid-phase synthesis           | 固相合成     | твердофазный синтез              | Festphasensynthèse            | Synthèse en phase solide    | 固相合成             |
| Molecular weight                | 分子量       | молекулярная масса               | Molekulargewicht              | Poids moléculaire           | 分子量               |
| Antimicrobial                   | 抗菌         | антимикробный                    | antimikrobiell                | antimicrobien               | 抗菌                 |
| Biosynthesis                    | 生物合成     | биосинтез                        | Biosynthese                   | Biosynthèse                 | 生合成               |

_This table must be expanded to ≥500 terms before translation begins._

#### 8.5.2 Glossary Governance

- Master glossary maintained as structured data (JSON/YAML)
- Version-controlled with translation memory tools (PO files, TMX)
- Approved by domain experts and professional translators
- Community suggestions accepted via pull request with expert review
- Consistency checks run automatically on all translated content
- Glossary updates propagated to all translations

### 8.6 Quality Assurance

#### 8.6.1 Linguistic Quality Metrics

| Metric                              | Target                | Measurement              |
| ----------------------------------- | --------------------- | ------------------------ |
| Translation coverage (per language) | ≥80% core content     | Automated inventory      |
| Glossary compliance                 | ≥95% term consistency | Automated check          |
| Spelling/grammar errors per page    | <2                    | Automated + human review |
| Cultural appropriateness score      | ≥4.5/5                | Expert review            |
| Localization review cycle           | ≤6 months             | Calendar tracking        |

#### 8.6.2 Technical Quality Checks

- Broken links in translated content
- Missing or incorrect hreflang tags
- Encoding issues (mojibake, garbled characters)
- Right-to-left rendering (for future languages)
- Date/time format correctness
- Number format correctness
- Image alt-text translation
- Form label translation
- Error message translation

### 8.7 Content Update Strategy for Multi-lingual

#### 8.7.1 Update Propagation

When English source content is updated:

1. **Change detection:** Automated diff between current and previous English version
2. **Impact assessment:** Classification of change severity (minor/critical)
3. **Translation priority:** Critical changes → immediate translation; Minor → batched
4. **Translation memory update:** New/changed segments added to TM
5. **Translation notification:** Translators notified of pending work
6. **Translation execution:** Priority-based queue processing
7. **Quality assurance:** Automated + human review
8. **Publication:** Staggered release per language
9. **Verification:** Post-publication quality spot-check

#### 8.7.2 Outdated Translation Management

- Automated flagging of content not reviewed within 12 months
- "Last reviewed" date prominently displayed on all pages
- User reporting mechanism for outdated translations
- Review priority queue based on page traffic and content age
- "Translation stale" warning banner for content exceeding review cycle

### 8.8 Regulatory and Compliance Considerations

#### 8.8.1 Regional Requirements

| Region         | Language    | Key Considerations                                                                                                   |
| -------------- | ----------- | -------------------------------------------------------------------------------------------------------------------- |
| Mainland China | ZH-CN       | ICP filing required; data localization; content censorship awareness; Great Firewall compatibility                   |
| Russia         | RU          | Federal law on personal data localization; language requirements for consumer-facing content                         |
| EU/EEA         | DE, FR      | GDPR compliance; accessibility requirements (European Accessibility Act); medical device regulations (if applicable) |
| Japan          | JP          | Act on Protection of Personal Information (APPI); Japanese pharmaceutical affairs law considerations                 |
| Canada         | FR (Quebec) | Bill 96 French language requirements for Quebec market                                                               |

#### 8.8.2 Medical/Health Disclaimer Requirements

All localized versions must include appropriate medical disclaimers in the local language, specifying:

- Content is for educational/reference purposes only
- Not a substitute for professional medical advice
- No clinical recommendations should be made based solely on site content
- Consult qualified healthcare professionals for medical decisions
- Local regulatory body contact information where applicable

---

## Appendices

### Appendix A: Glossary of Abbreviations

| Abbreviation | Full Form                                                  |
| ------------ | ---------------------------------------------------------- |
| ACE          | Angiotensin-Converting Enzyme                              |
| ADMET        | Absorption, Distribution, Metabolism, Excretion, Toxicity  |
| BLA          | Biologics License Application                              |
| cAMP         | Cyclic Adenosine Monophosphate                             |
| CD           | Circular Dichroism                                         |
| CL           | Clearance                                                  |
| CLSI         | Clinical and Laboratory Standards Institute                |
| Cmax         | Maximum Concentration                                      |
| CSF          | Cerebrospinal Fluid                                        |
| DPP          | Dipeptidyl Peptidase                                       |
| EDC          | 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide              |
| ER           | Endoplasmic Reticulum                                      |
| Fmoc         | Fluorenylmethyloxycarbonyl                                 |
| GPCR         | G-Protein Coupled Receptor                                 |
| GLP-1        | Glucagon-Like Peptide-1                                    |
| GnRH         | Gonadotropin-Releasing Hormone                             |
| HATU         | Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium   |
| HPLC         | High-Performance Liquid Chromatography                     |
| IC50         | Half-Maximal Inhibitory Concentration                      |
| IUPAC        | International Union of Pure and Applied Chemistry          |
| Ki           | Inhibition Constant                                        |
| Kd           | Dissociation Constant                                      |
| LCP          | Largest Contentful Paint                                   |
| MALDI-TOF    | Matrix-Assisted Laser Desorption/Ionization Time-of-Flight |
| MHC          | Major Histocompatibility Complex                           |
| MRSA         | Methicillin-Resistant Staphylococcus aureus                |
| MTPE         | Machine Translation Post-Editing                           |
| NDA          | New Drug Application                                       |
| NMR          | Nuclear Magnetic Resonance                                 |
| NRPS         | Non-Ribosomal Peptide Synthetase                           |
| PDB          | Protein Data Bank                                          |
| PK           | Pharmacokinetics                                           |
| PLM          | Phospholipid Monolayer                                     |
| QSAR         | Quantitative Structure-Activity Relationship               |
| RPO          | Recovery Point Objective                                   |
| RTO          | Recovery Time Objective                                    |
| SAR          | Structure-Activity Relationship                            |
| SPPS         | Solid-Phase Peptide Synthesis                              |
| TEA          | Triethylamine                                              |
| TFA          | Trifluoroacetic Acid                                       |
| TM           | Translation Memory                                         |
| Tmax         | Time to Maximum Concentration                              |
| TRH          | Thyrotropin-Releasing Hormone                              |
| Vd           | Volume of Distribution                                     |
| WCAG         | Web Content Accessibility Guidelines                       |

### Appendix B: Reference Database Identifiers

| Database           | Identifier Format         | Example     |
| ------------------ | ------------------------- | ----------- |
| UniProt            | P[0-9][A-Z0-9]{4}         | P01019      |
| PDB                | [0-9][A-Z0-9]{3}          | 1NRC        |
| ChEMBL             | CHEMBL[0-9]+              | CHEMBL4066  |
| PubChem CID        | [0-9]+                    | 16134794    |
| DrugBank           | DB[0-9]+                  | DB09043     |
| CAS                | [0-9]{2,7}-[0-9]{2}-[0-9] | 4474-91-3   |
| IUPHAR             | [0-9]+                    | 2283        |
| ClinicalTrials.gov | NCT[0-9]{8}               | NCT04266062 |

### Appendix C: Content Templates

Full content templates for each page type are maintained in the `/templates/` directory of the repository:

- `monograph-template.md` — encyclopeptide.com oligopeptide monograph
- `study-guide-template.md` — wikipept.com study guide
- `quiz-template.json` — wikipept.com quiz structure
- `flashcard-template.json` — wikipept.com flashcard deck structure
- `glossary-entry-template.json` — glossary term structure
- `translation-unit-template.json` — translation memory unit structure

---

**End of Document**

_This document is version-controlled. Changes require review by the domain analysis team. Next scheduled review: 2026-12-07._
